Press Release: Mereo BioPharma Reports Third Quarter 2026 Financial Results

Dow Jones11-09

Ongoing regulatory interactions in collaboration with Ultragenyx on potential path forward for setrusumab in osteogenesis imperfecta $(OI)$

Ongoing FDA interactions in collaboration with Sentynl Therapeutics to refine Phase 3 trial design for alvelestat in alpha-1 antitrypsin deficiency-associated lung disease (AATD-LD)

Cash and cash equivalents of $26.1 million at September 30, 2026, expected to fund operations into late-2027

LONDON, Nov. 09, 2026 (GLOBE NEWSWIRE) -- Mereo BioPharma Group plc $(MREO)$ ("Mereo" or the "Company"), a clinical-stage biopharmaceutical company focused on rare diseases, today announced financial results for the third quarter ended September 30, 2026, and provided an update on its late-stage programs.

"During the third quarter, we have made meaningful progress on our two core programs, setrusumab and alvelestat. These developments have the potential to set the stage for a transformational 2027 for Mereo, our shareholders and the patients we aim to serve," said Denise Scots-Knight, Chief Executive Officer of Mereo BioPharma. "In collaboration with our partner Ultragenyx, we are continuing to work closely with the regulators, to determine the necessary data to support a regulatory submission for setrusumab in OI and if there is a potential path forward. We believe that the data from post-hoc fracture analyses presented at the recent American Society for Bone and Mineral Research (ASBMR) Annual Meeting further support setrusumab's potential to provide meaningful benefit, particularly in pediatric, higher fracturing patients. We are also advancing our regulatory interactions on alvelestat for AATD-LD alongside Sentynl Therapeutics to streamline the Phase 3 design and are working to be in a position to initiate the Phase 3 study in early 2027. We continue to expect that our current cash position, which totaled $26.1 million as of September 30, will provide runway into late-2027, exclusive of the potential $40 million in upfront and R&D payments associated with the exercise of the alvelestat option by Sentynl and any other milestone payments which would further extend the runway."

Recent Developments and Anticipated Milestones

Setrusumab (UX143) for osteogenesis imperfecta (OI)

   -- Following the results of the Orbit and Cosmic Phase 3 studies of 
      setrusumab in OI, reported in December 2025, Mereo and its partner, 
      Ultragenyx Pharmaceutical, Inc. (Ultragenyx), have engaged with 
      regulatory agencies to determine a potential path forward for setrusumab 
      in pediatric OI patients. These interactions have focused on 
      understanding the necessary data to support a regulatory filing and if 
      there is a potential path forward. 
 
   -- Data from pre- and post-hoc analyses from both the Orbit and Cosmic 
      studies were presented at the 2026 ASBMR Annual Meeting held in October. 
      These data included baseline characteristics, as well as annual fracture 
      rate (AFR) analyses in certain patient subgroups. These pre- and post-hoc 
      analyses on total fractures in patients enrolled with at least 3 
      fractures in the prior 2 years showed a meaningful benefit on fractures, 
      bone mineral density and other endpoints in the two Phase 3 studies. 

Alvelestat (MPH-966) for alpha-1 antitrypsin deficiency-associated lung disease (AATD-LD)

   -- In August, Mereo announced an option and license agreement with Sentynl 
      Therapeutics, Inc. (Sentynl), a wholly owned subsidiary of Zydus 
      Lifesciences Limited, which granted Sentynl the right to acquire a 
      license for the U.S. commercial and global manufacturing rights to 
      alvelestat for AATD-LD. 
 
   -- Should Sentynl exercise its option during the short option period, Mereo 
      would receive $40 million in upfront and R&D payments which would provide 
      funding for the Phase 3 study. Mereo would also be eligible to receive up 
      to $435 million in regulatory and commercial milestones, as well as 
      double-digit tiered royalties on U.S. net sales of alvelestat. Mereo will 
      lead the global Phase 3 study and all regulatory interactions until study 
      completion. 
 
   -- Since signing the option and license agreement, the companies have been 
      collaborating to streamline the design of the planned Phase 3 study. In 
      parallel, Mereo has been working to be in a position to initiate the 
      Phase 3 study in early 2027. 
 
   -- Based on ongoing FDA interactions, Mereo expects to provide an update 
      before the end of the year. 

Vantictumab (OMP18R5) for autosomal dominant osteopetrosis type 2 (ADO2)

   -- āshibio, Inc. (āshibio), Mereo's development and commercial 
      partner for vantictumab, reported clinical biomarker data from a legacy 
      study of vantictumab in patients with cancer at the 2026 ASBMR Annual 
      Meeting. 
 
          -- These data showed that low doses of vantictumab (0.5-5mg/kg) 
             administered once weekly or once every two or three weeks, 
             increased osteoclast activity without inhibiting osteoblast 
             activity at these low doses. 
 
          -- Results were consistent with the findings from an ADO2 mouse study 
             presented by āshibio at the 2025 ASBMR Annual Meeting showing 
             that low doses of vantictumab increased osteoclast activity and 
             rescued the osteopetrotic bone phenotype in this animal model. 
   -- āshibio is continuing to advance vantictumab toward clinical trials 
      in patients with ADO2 and intends to initiate trials in the first half of 
      2028. 

Third Quarter 2026 Financial Results

Total research and development ("R&D") expenses decreased by $2.2 million, from $4.3 million in the third quarter of 2025 to $2.1 million in the third quarter of 2026. The decrease was primarily due to reductions of $1.6 million in R&D expenses for setrusumab and $0.4 million for alvelestat. The decrease in program expenses for setrusumab was primarily driven by reductions of, and delays to, investment in manufacturing and ongoing activities, including medical affairs activities in Europe during the third quarter of 2026. The decrease in program expenses for alvelestat was primarily due to the completion of activities undertaken in 2025 in preparation for a potential Phase 3 study.

General and administrative ("G&A") expenses decreased by $1.1 million, from $6.0 million in the third quarter of 2025 to $4.9 million in the third quarter of 2026. The decrease was primarily due to reductions in investment in pre-commercial activities to lay the foundation for the potential commercial launch of setrusumab in Europe, and other realized net cost savings.

Net loss for the third quarter of 2026 was $5.9 million, compared to $7.0 million for the third quarter of 2025, primarily reflecting reductions in R&D and G&A expenses, partially offset by a lower net foreign currency translation gain.

As of September 30, 2026, the Company had cash and cash equivalents of $26.1 million, compared to $41.0 million as of December 31, 2025. The Company expects, based on current operational plans, that its existing cash and cash equivalents balance will enable it to fund its currently committed clinical trials, operating expenses, and capital expenditure requirements into late 2027. This guidance does not include any future potential payments associated with business development activity around any of the Company's programs.

Total ordinary shares issued as of September 30, 2026 were 798,454,864. Total ADS equivalents as of September 30, 2026 were 159,690,972, with each ADS representing five ordinary shares of the Company.

About Mereo BioPharma

Mereo BioPharma is a biopharmaceutical company focused on the development of innovative therapeutics for rare diseases. The Company has three rare disease product candidates: setrusumab for the treatment of osteogenesis imperfecta (OI); alvelestat for the treatment of alpha-1 antitrypsin deficiency-associated lung disease (AATD-LD); and vantictumab for the treatment of autosomal dominant osteopetrosis type 2 (ADO2). The Company seeks to combine partnerships that provide validation for its programs and non-dilutive capital to fund late-stage clinical development, with the upside of retaining commercial rights in key strategic territories, including Europe. The Company and its partner for setrusumab, Ultragenyx Pharmaceutical Inc., have reported top-line results from two Phase 3 studies for setrusumab in OI in patients aged 2 to 25 years old. Ultragenyx is funding and leading global development and Mereo has retained EU and UK commercial rights. Mereo has entered into an exclusive option and license agreement with Sentynl Therapeutics Inc. for the U.S. rights to commercialize alvelestat for AATD-LD, while retaining rest of the world rights and will lead the global development. The agreement also grants Sentynl global rights to manufacture alvelestat for AATD-LD. Mereo has partnered with āshibio, Inc., for vantictumab in autosomal dominant osteopetrosis type 2 (ADO2). āshibio, Inc. is funding and leading the global development program and Mereo has retained EU and UK commercial rights. Mereo has also entered into exclusive global license agreements with ReproNovo SA, for the development and commercialization of leflutrozole for the treatment of infertility in men, and with Feng Biosciences for the development and commercialization of navicixizumab for late-stage ovarian cancer.

Forward-Looking Statements

This press release contains "forward-looking statements" that involve substantial risks and uncertainties, as well as assumptions that, if they never materialize or prove incorrect, could cause our results to differ materially from those expressed or implied by such forward-looking statements. All statements other than statements of historical fact contained herein are forward-looking statements within the meaning of Section 27A of the United States Securities Act of 1933, as amended, and Section 21E of the United States Securities Exchange Act of 1934, as amended. Forward-looking statements reflect our current expectations, beliefs and assumptions concerning future events or our future financial performance and involve known and unknown risks, uncertainties and other factors that may cause our actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by these forward-looking statements. Risks and uncertainties include, among other things, the uncertainties inherent in the clinical development process; the Company's reliance on third parties to conduct and provide funding for its clinical trials; the sufficiency of existing cash to fund operations and/or the inability to raise additional funding on favorable terms or at all; the uncertainty inherent in regulatory review processes, including varying interpretations and analyses of data from clinical trials; the Company's dependence on enrollment of patients in its clinical trials; potentially smaller than anticipated market opportunities for the Company's product candidates; the Company's dependence on its key executives; and the Company's ability to maintain compliance with Nasdaq continued listing requirements.

You should carefully consider the foregoing factors and the other risks and uncertainties that affect the Company's business, including those described in the "Risk Factors" section of its Annual Report on Form 10-K, as well as discussions of potential risks, uncertainties, and other important factors in the Company's subsequent filings with the Securities and Exchange Commission. Forward-looking statements are often identified by the words "believe," "expect," "anticipate," "plan," "intend," "foresee," "should," "would," "could," "may," "estimate," "outlook," "will," "continue" and similar expressions, including the negative thereof. The absence of these words, however, does not mean that the statements are not forward-looking. These forward-looking statements are based on the Company's current expectations, beliefs and assumptions concerning future developments and business conditions and their potential effect on the Company. While management believes that these forward-looking statements are reasonable as and when made, there can be no assurance that future developments affecting the Company will be those that it anticipates. The Company wishes to caution you not to place undue reliance on any forward-looking statements, which speak only as of the date hereof. The Company undertakes no obligation to publicly update or revise any of our forward-looking statements after the date they are made, whether as a result of new information, future events or otherwise, except to the extent required by law.

 
 
  Mereo BioPharma Contacts: 
Mereo                                                      +44 (0)333 023 7300 
Denise Scots-Knight, Chief Executive Officer 
Christine Fox, Chief Financial Officer 
 
Burns McClellan (Investor Relations Adviser to 
 Mereo)                                                       +01 646 930 4406 
Lee Roth 
Investors                                         investors@mereobiopharma.com 
                                                  ---------------------------- 
 
 
 
                        MEREO BIOPHARMA GROUP PLC 
                   CONDENSED CONSOLIDATED BALANCE SHEETS 
            (In thousands, except share and per share amounts) 
                                (Unaudited) 
 
                                        September 30,     December 31, 
                                       ---------------   -------------- 
                                            2026              2025 
                                       ---------------   -------------- 
Assets 
   Current assets: 
     Cash and cash equivalents          $       26,097    $      40,992 
     Prepaid expenses and other 
      current assets                             2,269            2,531 
     Research and development 
      incentives receivables                       306            1,497 
                                           -----------       ---------- 
   Total current assets                         28,672           45,020 
   Property and equipment, net                      24              137 
   Operating lease right-of-use 
    assets, net                                    758              244 
   Intangible assets, net                          129              516 
                                           -----------       ---------- 
Total assets                            $       29,583    $      45,917 
                                           ===========       ========== 
 
Liabilities 
   Current liabilities: 
     Accounts payable                   $        1,004    $       1,333 
     Accrued expenses                            3,017            2,026 
     Operating lease liabilities -- 
      current                                      577              202 
     Warrant liabilities -- current                  8               -- 
     Other current liabilities                     888              741 
                                           -----------       ---------- 
   Total current liabilities                     5,494            4,302 
   Warrant liabilities -- non-current                8               38 
   Other non-current liabilities                   370              661 
                                           -----------       ---------- 
Total liabilities                       $        5,872    $       5,001 
                                           ===========       ========== 
 
Shareholders' Equity 
   Ordinary shares, par value 
    GBP0.003 per share; 798,454,864 
    shares issued at September 30, 
    2026 (December 31, 2025: 
    795,658,504)                        $        3,146    $       3,135 
   Additional paid-in capital                  553,243          549,622 
   Accumulated deficit                        (520,406)        (501,018) 
   Accumulated other comprehensive 
    loss                                       (12,272)         (10,823) 
                                           -----------       ---------- 
Total shareholders' equity              $       23,711    $      40,916 
                                           ===========       ========== 
Total liabilities and shareholders' 
 equity                                 $       29,583    $      45,917 
                                           ===========       ========== 
 
 
 
 
                           MEREO BIOPHARMA GROUP PLC 
                        CONDENSED CONSOLIDATED STATEMENTS 
                      OF OPERATIONS AND COMPREHENSIVE LOSS 
               (In thousands, except share and per share amounts) 
                                   (Unaudited) 
 
                        Three Months Ended             Nine Months Ended 
                           September 30,                 September 30, 
                    ---------------------------   --------------------------- 
                        2026           2025           2026           2025 
                    ------------   ------------   ------------   ------------ 
Revenue             $        800   $         --   $        800   $        500 
Operating expenses 
   Cost of revenue            --             --             --           (133) 
   Research and 
    development           (2,090)        (4,270)        (8,645)       (13,573) 
   General and 
    administrative        (4,928)        (6,045)       (14,169)       (18,811) 
   Other income               --            300             --            300 
                     -----------    -----------    -----------    ----------- 
Loss from 
 operations               (6,218)       (10,015)       (22,014)       (31,717) 
Other 
income/(expenses) 
Interest income              241            504            846          1,752 
Interest expense             (10)           (28)           (47)          (232) 
Changes in the 
 fair value of 
 warrants                     (2)           196             21            511 
Foreign currency 
 transaction 
 gain/(loss), net             29          1,873          1,296         (6,218) 
Benefit from 
 research and 
 development tax 
 credit                       97            446            311          1,377 
                     -----------    -----------    -----------    ----------- 
Net loss before 
 income tax               (5,863)        (7,024)       (19,587)       (34,527) 
Income tax benefit            --             --             --             -- 
                     -----------    -----------    -----------    ----------- 
Net loss            $     (5,863)  $     (7,024)  $    (19,587)  $    (34,527) 
                     ===========    ===========    ===========    =========== 
 
Loss per share -- 
 basic and 
 diluted            $      (0.01)  $      (0.01)  $      (0.02)  $      (0.04) 
Weighted average 
 shares 
 outstanding -- 
 basic and 
 diluted             804,533,827    799,947,013    803,310,695    796,018,903 
 
Net loss            $     (5,863)  $     (7,024)  $    (19,587)  $    (34,527) 
Other 
 comprehensive 
 income/(loss) -- 
 Foreign currency 
 translation 
 adjustments, net 
 of tax                       13         (2,267)        (1,449)         7,939 
                     -----------    -----------    -----------    ----------- 
Total 
 comprehensive 
 loss               $     (5,850)  $     (9,291)  $    (21,036)  $    (26,588) 
                     ===========    ===========    ===========    =========== 
 

At the request of the copyright holder, you need to log in to view this content

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap
Leave a comment